Get the Stockscreener App
0.6939
7.16%
-0.0535
After Hours:
.67
-0.0239
-3.44%
Oncternal Therapeutics Inc stock is traded at $0.6939, with a volume of 219.69K.
It is down -7.16% in the last 24 hours and down -54.65% over the past month.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
See More
Previous Close:
$0.7474
Open:
$0.72
24h Volume:
219.69K
Relative Volume:
1.79
Market Cap:
$2.05M
Revenue:
-
Net Income/Loss:
$-39.48M
P/E Ratio:
-0.913
EPS:
-0.76
Net Cash Flow:
$-32.16M
1W Performance:
-39.13%
1M Performance:
-54.65%
6M Performance:
-92.38%
1Y Performance:
-90.36%
1-Day Range:
$0.6566
$0.74
1-Week Range:
$0.62
$0.84
52-Week Range:
$0.62
$13.14
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Name
Oncternal Therapeutics Inc
Sector
Industry
Phone
(858) 434-1113
Address
12230 EL CAMINO REAL, SAN DIEGO, CA
Compare ONCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCT
Oncternal Therapeutics Inc
|
0.6939 | 2.05M | 0 | -39.48M | -32.16M | -13.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Initiated | Oppenheimer | Outperform |
| Feb-23-21 | Initiated | Northland Capital | Outperform |
Oncternal Therapeutics Inc Stock (ONCT) Latest News
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
ONCT stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
ONCT stock touches 52-week low at $0.83 amid market challenges - Investing.com
Oncternal shares to be delisted from Nasdaq - Investing.com
Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks
ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com
Oncternal announces workforce reduction, executive changes - Investing.com
Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks
ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com
Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com
Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia
Oncternal reports positive prostate cancer treatment results - Investing.com India
Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire
B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World
ONCT Stock Touches 52-Week Low at $1.19 Amid Market Challenges - Investing.com Australia
Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements in Clinical ... - Yahoo Finance Australia
Oncternal stock jumps 9% on FDA fast track designation - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% - MSN
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com Australia
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Oncternal Therapeutics (ONCT) - Defense World
Omnicell Appoints Nnamdi Njoku as New COO - TipRanks
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK
ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily
On Holding's Options Frenzy: What You Need to Know - Benzinga
This Option Provides Gains By Coasting With On Running Shoes - Investor's Business Daily
ONON’s valuation metrics: A comprehensive analysis - US Post News
OM Stock on the Rise: A Promising Investment - The InvestChronicle
Was Outset Medical Inc (OM)’s session last reading good? - US Post News
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News
Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Outset Medical (OM) Shares Down 94% Since Disclosing FDA - GlobeNewswire
On Holding Options Trading: A Deep Dive into Market Sentiment - Benzinga
ON (NYSE:ONON) Rating Increased to Neutral at Bank of America - MarketBeat
OM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Onsemi Could Be Set Up For a Solid Rebound: Here's Why - MarketBeat
Kayne Anderson Rudnick Investment Management LLC Boosts Stock Position in On Holding AG (NYSE:ONON) - MarketBeat
Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Tuesday, September 24th - Defense World
Bradley Foster & Sargent Inc. CT Increases Stock Position in On Holding AG (NYSE:ONON) - Defense World
Onsemi (NASDAQ:ON) Holdings Raised by Argent Trust Co - Defense World
Oncternal Therapeutics Inc Stock (ONCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):